Europe

Quintiles to offer jobs to 100 Merck Serono employees affected by cuts

Wednesday, June 27, 2012 10:16 AM

CRO Quintiles has committed to make at least 100 employment offers within the next three months to Merck Serono employees primarily working in global development and medical function in Geneva.

More... »

Accovion GmbH expands global presence in Spain

Monday, June 25, 2012 10:31 AM

Accovion GmbH, a full-service provider of clinical development services based in Eschborn, Germany, has launched an additional subsidiary in Spain.

More... »

DSM inks major commercial agreement for its XD technology

Wednesday, June 20, 2012 11:55 AM

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, has signed a commercial agreement for contract manufacturing services using its proprietary XD high cell density process technology with a major pharma company.

More... »

Merck Serono announces final efficiency program for Switzerland

Wednesday, June 20, 2012 10:03 AM

After a long consultation process, Merck Serono, the biopharmaceutical division of Merck, had made its final plan for restructuring its operations in Switzerland, closing its Geneva and Coinsins sites.

More... »

Trophos appoints Christine Placet as CEO

Monday, June 18, 2012 12:22 PM

Trophos, a French clinical stage pharmaceutical company developing therapeutics for under-served needs in neurology and cardiology, has appointed Christine Placet as chief executive officer.

More... »

Trial Masters and Zeincro merge to create specialist CRO in South-Eastern Europe

Thursday, June 14, 2012 10:00 AM

Zeincro, a specialist provider of clinical research services in Greece, Turkey and Cyprus, is merging with Trial Masters, a CRO managing clinical trials in Hungary and Romania.

More... »

Novartis’ Gilenya earns positive results in extended phase III head-to-head study

Monday, June 11, 2012 02:52 PM

New long-term data for Gilenya (fingolimod), the only oral therapy approved to treat people with relapsing forms of multiple sclerosis (MS), show a sustained efficacy benefit and a consistent safety profile with up to 4.5 years of continuous treatment, according to Switzerland-based Novartis Pharma.

More... »

EMA boosts transparency with online publication of suspected side effects

Friday, June 1, 2012 11:28 AM

The European Medicines Agency has begun publishing suspected side effect reports for medicines authorized in the European Economic Area (EEA) on a new public website: www.adrreports.eu.

More... »

CMO revenue could double in Europe, says Frost & Sullivan

Thursday, May 31, 2012 03:10 PM

New analysis from Frost & Sullivan, "European Pharmaceutical and Biotech Contract Manufacturing Markets," finds that the European pharmaceutical contract manufacturing market earned revenues of $10.02 billion in 2011 and estimates this to reach $20.75 billion in 2018. Over the same period, the European biotech contract manufacturing market is set to expand from $1.21 billion to an estimated $2.67 billion.

More... »

‘Life Science Panorama 2011’ report looks at France

Wednesday, May 23, 2012 11:13 AM

France Biotech, the French association of life science companies, in partnership with Ernst & Young, published the 10th annual “Life Science Panorama,” describing the industry's main trends for 2010-2011 in France and worldwide.

More... »